The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

Shares in Verve Therapeutics ( VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly ( LLY -2.54%) to ...

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Solar stocks tumbled after Senate Republicans maintained a full phase-out of [solar and wind-energy tax credits]( ...

This discount is shown at checkout, if applicable. Eli Lilly and Company says it will acquire the gene therapy start-up Verve Therapeutics for $1.3 billion. Verve’s lead drug candidate, VERVE-102, ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of Verve’s one-time treatments are in the clinic. Lead ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...